The Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospective Study

• Main Authors: Sara Galimberti (Author), Elena Ciabatti (Author), Giacomo Ercolano (Author), Susanna Grassi (Author), Francesca Guerrini (Author), Nadia Cecconi (Author), Martina Rousseau (Author), Giulia Cervetti (Author), Francesco Mazziotta (Author), Lorenzo Iovino (Author), Franca Falzetti (Author), Flavio Falcinelli (Author), Alberto Bosi (Author), Luigi Rigacci (Author), Sofia Kovalchuk (Author), Daniele Vallisa (Author), Lucia Macchia (Author), Eugenio Ciancia (Author), Mario Petrini (Author)
• Format: Book
• Published: Frontiers Media S.A., 2017-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

R-Bendamustine is an effective treatment for follicular lymphoma (FL). Previous large trials demonstrated the prognostic role of the molecular minimal residual disease (MRD) during the most frequently adopted chemotherapeutic regimens, but there are not yet conclusive data about the effect of combin...